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LETTERS TO THE EDITOR 
Mediastinal lymph node metastasis in patients 
with clinical stage I lung cancer 
To the Editor." 
I read the recent article by Takizawa and associates 1 
regarding mediastinal lymph node metastasis n patients 
with clinical stage I peripheral non-small-cell lung cancer 
(NSCLC) with great interest. This important study in 575 
patients nicely demonstrates that even in clinical stage I
NSCLC, 14% of patients have N2 disease, moving them 
into stage IIIA. In 68% of these N2 cases, the surgeon 
could not detect the lymph node metastases by macro- 
scopic examination, a fact that stresses the importance of 
complete nodal sampling. 
However, it is surprising that in the discussion the 
authors do not address the role of mediastinoscopy in 
preoperative staging of lung cancer. When looking care- 
fully at Tables III to VII, I observed a total of 79 patients 
with N2 disease; in 61 patients (77.2%) these N2 nodes 
were accessible by cervical mediastinoscopy and in 16 
patients (20.3%) by left anterior mediastinoscopy. If rou- 
tine cervical mediastinoscopy had been performed for 
right-sided tumors, and combined with an anterior or 
extended mediastinoscopy for left-sided tumors, 77 of 79 
or 97.5% of these N2 metastases would have been de- 
tected before the operation. The accuracy of mediastinos- 
copy has been shown to be 95% for superior mediastinal 
involvement. 2 Another advantage of mediastinoscopy is 
contralateral sampling of lymph nodes, which detects 
possible N3 disease. Inasmuch as contralateral node sam- 
pling is difficult by way of a lateral thoracotomy, some 
patients in the study by Takizawa's group, especially those 
with multilevel N2 disease, could have had N3 and thus 
stage IIIB disease. 
Recently, the role of mediastinoscopy has become more 
important because surgery is no longer advocated as 
primary treatment for NSCLC with histologically proved 
N2 involvement. Because overall survival in these patients 
is very poor, many of them are treated by induction 
chemotherapy,3.4 It would be interesting to know the 
overall survival data of the 79 patients with N2 disease in 
the study by Takizawa's group, ~ in which none of the 
patients had preoperative mediastinoscopy and all were 
treated by primary surgery. In my opinion, mediastinos- 
copy should be performed routinely for correct staging of 
NSCLC, because the accuracy of present-day computed 
tomographic s anners in mediastinal staging remains low. 5 
Primary consideration should be given to induction che- 
motherapy in patients with N2 involvement, avoiding 
primary surgical treatment. 
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Reply to the Editor: 
We appreciate Dr. Van Schil's investigation of the 
data with regard to our patients with N2 disease. His 
investigation shows us that 97.5% of the N2 metastases 
of our patients would have been detected in the preop- 
erative period if cervical or anterior mediastinoscopy 
had been performed. We realize that Dr. Van Schil 
recommends performing mediastinoscopy to detect N2 
disease before thoracotomies. We do not agree with his 
recommendation. We did not perform mediastinoscopy 
in our patients with clinical stage I lung cancer because 
the negative predictive accuracy for mediastinal lymph 
node metastasis with the use of computed tomography 
is high. ~'a Each patient in our article had clinical stage I
lung cancer, which was assessed through computed 
tomography. No patients had enlarged mediastinal 
lymph nodes suggestive of N2 disease. We would have 
had to perform mediastinoscopy on all patients with 
clinical stage I lung cancer to detect N2 disease among 
them. If we had done so, 496 of 575 patients (86%) 
would have been subjected to a needless invasive 
operation. Therefore we think that the practicality of 
performing mediastinoscopy on all patients with clinical 
stage I lung cancer merits further debate. 
Dr. Van Schil asked about the overall survival data of 
the 79 patients with N2 disease in our study. We followed 
up all of our 79 patients with N2 disease. Their overall 
survival, calculated by means of the Kaplan-Meier 
method, was estimated to be 26% at 5 years. Each death 
decreased the proportion surviving in our calculations, 
regardless of the cause of death. Although we believe that 
our surgical treatment for patients with N2 disease is 
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